SCHEMBL311509

SCHEMBL311509

O=c1cc(-c2ccc(O)c(O)c2)oc2cccnc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 6/20 0.62
ALOX5 P09917 5/20 0.62
KDM4E B2RXH2 4/20 0.62
MAPT P10636 4/20 0.62
CYP3A4 P08684 3/20 0.62
ALOX15 P16050 3/20 0.62
HSD17B10 Q99714 3/20 0.62
IP6K2 Q9UHH9 3/20 0.62
TNKS O95271 3/20 0.62
PARP1 P09874 3/20 0.62
TNKS2 Q9H2K2 3/20 0.62
MEN1 O00255 3/20 0.62
RECQL P46063 3/20 0.62
KMT2A Q03164 3/20 0.62
MAPK1 P28482 2/20 0.62
CYP2C9 P11712 2/20 0.62
ALOX12 P18054 2/20 0.62
CYP2C19 P33261 2/20 0.62
ALDH1A1 P00352 2/20 0.62
HPGD P15428 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312584 0.86 KDM4E (0.49) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL311223 0.86 KDM4E (0.60) POLHKDM4EMAPTCYP3A4ALOX15
SCHEMBL312234 0.80 POLH (0.50) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL312857 0.80 POLH (0.53) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL313143 0.78 MEN1 (0.62) POLHKDM4EMAPTCYP3A4ALOX15
SCHEMBL312399 0.78 KDM4E (0.62) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL30591245 0.77 CYP3A4 (1.00) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL29664745 0.77 TNKS (1.00) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL3817277 0.77 CYP3A4 (1.00) POLHALOX5KDM4EMAPTCYP3A4
SCHEMBL345706 0.77 TNKS (1.00) POLHALOX5KDM4EMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 POLH 4318/4885ALOX5 986/4885KDM4E 3504/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 POLH 4318/4885ALOX5 986/4885KDM4E 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.